Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001558370-23-004211
Filing Date
2023-03-20
Accepted
2023-03-20 17:19:01
Documents
110
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K rvlp-20221231x10k.htm   iXBRL 10-K 2516147
2 EX-10.26 rvlp-20221231xex10d26.htm EX-10.26 48993
3 EX-21.1 rvlp-20221231xex21d1.htm EX-21.1 7861
4 EX-23.1 rvlp-20221231xex23d1.htm EX-23.1 7162
5 EX-31.1 rvlp-20221231xex31d1.htm EX-31.1 9679
6 EX-32.1 rvlp-20221231xex32d1.htm EX-32.1 8469
7 GRAPHIC rvlp-20221231x10k002.jpg GRAPHIC 18674
8 GRAPHIC rvlp-20221231x10k003.jpg GRAPHIC 21689
  Complete submission text file 0001558370-23-004211.txt   11900377

Data Files

Seq Description Document Type Size
9 EX-101.SCH rvlp-20221231.xsd EX-101.SCH 79620
10 EX-101.CAL rvlp-20221231_cal.xml EX-101.CAL 103943
11 EX-101.DEF rvlp-20221231_def.xml EX-101.DEF 364319
12 EX-101.LAB rvlp-20221231_lab.xml EX-101.LAB 741182
13 EX-101.PRE rvlp-20221231_pre.xml EX-101.PRE 617772
104 EXTRACTED XBRL INSTANCE DOCUMENT rvlp-20221231x10k_htm.xml XML 2082384
Mailing Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807
Business Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807 9088091300
RVL Pharmaceuticals plc (Filer) CIK: 0001739426 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38709 | Film No.: 23747148
SIC: 2834 Pharmaceutical Preparations